Recent advances in idiopathic pulmonary fibrosis

Sanghoon Park; Eun Joo Lee

doi:10.4046/trd.2013.74.1.1

Recent advances in idiopathic pulmonary fibrosis

Sanghoon Park, Eun Joo Lee

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright

Original language	English
Pages (from-to)	1-6
Number of pages	6
Journal	Tuberculosis and Respiratory Diseases
Volume	74
Issue number	1
DOIs	https://doi.org/10.4046/trd.2013.74.1.1
Publication status	Published - 2013 Jan
Externally published	Yes

Bibliographical note

Funding Information:
This research was supported in part by National Institutes of Health, National Heart, Lung, and Blood Institute grants P50HL-56402 and 2 K24 HL04212.

Keywords

Clinical trial
Etiology
Idiopathic pulmonary fibrosis

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4046/trd.2013.74.1.1

Cite this

@article{faa34a008629445a98ca31371a6ef963,

title = "Recent advances in idiopathic pulmonary fibrosis",

abstract = "The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright",

keywords = "Clinical trial, Etiology, Idiopathic pulmonary fibrosis",

author = "Sanghoon Park and Lee, {Eun Joo}",

note = "Funding Information: This research was supported in part by National Institutes of Health, National Heart, Lung, and Blood Institute grants P50HL-56402 and 2 K24 HL04212. ",

year = "2013",

month = jan,

doi = "10.4046/trd.2013.74.1.1",

language = "English",

volume = "74",

pages = "1--6",

journal = "Tuberculosis and Respiratory Diseases",

issn = "1738-3536",

publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",

number = "1",

}

TY - JOUR

T1 - Recent advances in idiopathic pulmonary fibrosis

AU - Park, Sanghoon

AU - Lee, Eun Joo

N1 - Funding Information: This research was supported in part by National Institutes of Health, National Heart, Lung, and Blood Institute grants P50HL-56402 and 2 K24 HL04212.

PY - 2013/1

Y1 - 2013/1

N2 - The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright

AB - The concept on idiopathic pulmonary fibrosis (IPF) pathogenesis has progressed from chronic inflammation to aberrant wounding healing and even more to the current paradigms of a multifactorial and heterogeneous disease process. Despite the growth of clinical trials for IPF, most of the results, including N-acetylcysteine combination, warfarin, and bosentan, were disappointing. On the other hand, there have been a number of important developments; the foremost is the licensing of pirfenidone in Europe and Asia. In this article, we briefly review the recent knowledge of pathogenesis of IPF. We also summarize the recent clinical trials regarding the management of IPF. Copyright

KW - Clinical trial

KW - Etiology

KW - Idiopathic pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84874475811&partnerID=8YFLogxK

U2 - 10.4046/trd.2013.74.1.1

DO - 10.4046/trd.2013.74.1.1

M3 - Review article

C2 - 23390446

AN - SCOPUS:84874475811

SN - 1738-3536

VL - 74

SP - 1

EP - 6

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

IS - 1

ER -

Recent advances in idiopathic pulmonary fibrosis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this